The decreased achievement of therapeutic goal in lipid lowering therapy in obese and diabetic patients in Poland

Jankowski, 2011, Lipid-lowering drugs and control of hypercholesterolemia in Poland: recent evidence, Pol Arch Med Wewn, 121, 164 Bandosz, 2015, A victory for statins or a defeat for diet policies? Cholesterol falls in Poland in the past decade: a modeling study, Int J Cardiol, 185, 313, 10.1016/j.ijcard.2015.03.079 Van Ganse, 2005, Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study, Curr Med Res Opin, 9, 1389, 10.1185/030079905X59139 März, 1999, Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial), Am J Cardiol, 84, 7, 10.1016/S0002-9149(99)00183-6 Bożentowicz-Wikarek, 2012, Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis–guidelines vs reality, Pharmacol Rep, 64, 377, 10.1016/S1734-1140(12)70778-8 Halava, 2014, Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities, CMAJ, 186, E449, 10.1503/cmaj.131807 Nag, 2007, LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO, J Manag Care Pharm, 13, 652, 10.18553/jmcp.2007.13.8.652 Cybulska, 2012, Achieving target low-density lipoprotein cholesterol levels in the Polish population, Pol Arch Med Wewn, 122, 9 World Health Organization, 2005, The challenge of obesity in the WHO European Region, Fact Sheet EURO, 13, 1 Alberti, 2005, IDF epidemiology task force consensus group. The metabolic syndrome–a new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8 Reiner, 2011, ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J, 32, 1769, 10.1093/eurheartj/ehr158 Zdrojewski, 2015, A new version of cardiovascular risk assessment system and risk charts calibrated for Polish population, Kardiol Pol, 10, 958, 10.5603/KP.2015.0182 Eliasson, 2011, Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus-an observational study from the Swedish National Diabetes Register, PLoS One, 4, e18744, 10.1371/journal.pone.0018744 Krempf, 2015, Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey, Lipids Health Dis, 14, 45, 10.1186/s12944-015-0037-y Goldman, 2006, Patients’ perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies, Ann Fam Med, 4, 205, 10.1370/afm.534 Bruckert, 2012, Cross-analysis of dietary prescriptions and adherence in 356 hypercholesterolaemic patients, Arch Cardiovasc Dis, 105, 557, 10.1016/j.acvd.2012.06.005 Lang, 2001, Declared knowledge, beliefs and practices for cardiovascular disease prevention in the French population, Rev Epidemiol Sante Publique, 49, 239 Hobbs, 2002, Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey, Fam Pract, 19, 596, 10.1093/fampra/19.6.596 Durack-Bown, 2003, Patients’ and physicians’ perceptions and experience of hypercholesterolaemia: a qualitative study, Br J Gen Pract, 53, 851 Olszanecka-Glinianowicz, 2013, The level of health education in the Polish population, Ann Agric Environ Med, 20, 559 Frolkis, 1998, Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines, Circulation, 98, 851, 10.1161/01.CIR.98.9.851 Nicholls, 2006, Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study), Am J Cardiol, 97, 1553, 10.1016/j.amjcard.2005.12.042 Gill, 2004, Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects, Atherosclerosis, 176, 49, 10.1016/j.atherosclerosis.2004.04.022 Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S1, 10.1161/01.cir.0000437738.63853.7a